Novavax, Inc.
NVAX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $1.12B | $682M | +64.7% |
| Operating income | $453M | −$249M | |
| Net income | $440M | −$188M |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $68.3M | $70.4M | −3.0% |
| Operating income | −$31.3M | −$178M | +82.4% |
| Net income | −$31.4M | −$202M | +84.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Novavax's revenue in FY2025?
- $1.12B in FY2025 (Fiscal year ended Dec 31, 2025), +64.7% vs $682M a year earlier, per its 10-K filed Feb 2026.
- Was Novavax profitable in FY2025?
- Yes: net income was $440M and operating income $453M in FY2025.
- What was Novavax's revenue in Q3 2026?
- $68.3M (−3.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.